Skip to contentScholarGate
LibraryBookshelfDeskReview StudioAssistant
Sign in
On this page
IntuitionHow it worksWhen to use itStrengths & limitationsCommon pitfallsApplicationsFrequently asked🔒 Read the full methodSourcesRelated methods
Cite this pageSpotted an issue on this page? Report or suggest a fix →
Home›Epidemiology›Pragmatic Kaplan-Meier Analysis — Survival Estimation in Real-World Settings
Process / pipelineClinical / epidemiology

Pragmatic Kaplan-Meier Analysis — Survival Estimation in Real-World Settings

Pragmatic Kaplan-Meier Survival Analysis · Also known as: pragmatic KM analysis, real-world Kaplan-Meier, pragmatic survival curve estimation, KM analysis in pragmatic trials

Pragmatic Kaplan-Meier analysis applies the non-parametric Kaplan-Meier product-limit estimator to time-to-event data collected under real-world or pragmatic conditions — diverse populations, routine clinical care, minimal exclusions, and standard-of-care comparators. Unlike explanatory trials designed to isolate a treatment effect under ideal conditions, pragmatic designs accept real-world heterogeneity, and the resulting survival curves reflect the effectiveness of an intervention as it actually performs in clinical practice.

ScholarGate
  1. Process / pipeline
  2. v1
  3. 2 Sources
  4. PUBLISHED
Cite this page →
Tools & resources
Download slides
Learn & explore

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Method map

The neighbourhood of related methods — select a node to explore.

Pragmatic Kaplan-Meier analysis
Cox proportional hazardsKaplan-Meier AnalysisLog-Rank TestPragmatic randomized cli…Survival Analysis

When to use it

Use pragmatic Kaplan-Meier analysis when the research question is about real-world effectiveness — how an intervention performs across the heterogeneous patients, providers, and settings found in routine care — and time-to-event is the primary outcome. It is the appropriate choice when data come from electronic health records, administrative claims, disease registries, or large pragmatic trials with broad eligibility. Do not use it when the goal is to establish biological or mechanistic efficacy under tightly controlled conditions (use an explanatory RCT instead), when proportional-hazard modeling of covariates is needed (use Cox regression), or when the event data are insufficient to produce stable step-function estimates (very small samples with few events yield wide confidence intervals and unreliable curves).

Strengths & limitations

Strengths
  • Non-parametric — makes no assumption about the underlying survival distribution, making it robust to skewed time-to-event data common in real-world populations.
  • Handles censoring correctly — patients lost to follow-up or still event-free at study end contribute their observed time without distorting the estimate.
  • Produces an immediately interpretable visual summary — the step-function survival curve communicates results to clinicians without requiring statistical expertise.
  • Captures real-world effectiveness across diverse patients and settings, maximizing external validity and generalizability to clinical practice.
  • Easily stratified — separate curves per treatment arm, site, or patient subgroup can be overlaid for direct visual comparison.
Limitations
  • Cannot adjust for confounding covariates within the estimator itself — confounding must be addressed externally (e.g., propensity scoring, stratification) before or alongside the Kaplan-Meier step.
  • Assumes non-informative censoring — if patients drop out because they are deteriorating, the survival estimate is biased upward.
  • Pragmatic settings introduce treatment heterogeneity (protocol deviations, co-interventions, dose changes) that can dilute treatment contrasts compared to explanatory trials.
  • Median survival cannot be estimated if fewer than 50% of participants experience the event during follow-up, a common problem in long-horizon pragmatic studies.

Frequently asked

What makes a Kaplan-Meier analysis 'pragmatic' rather than standard?

The distinction lies in the study design context, not the estimator itself. A pragmatic KM analysis uses data from broadly eligible, diverse real-world populations under routine care conditions — often from registries, EHR data, or pragmatic trials with minimal exclusions. A standard explanatory KM analysis comes from tightly controlled trials designed to isolate biological efficacy. The pragmatic version prioritizes external validity and real-world generalizability; the explanatory version prioritizes internal validity and causal certainty.

Should I adjust for confounders before plotting KM curves in a pragmatic analysis?

Yes, when comparing non-randomized groups. Raw KM curves in observational or pragmatic registry data typically reflect both the treatment effect and baseline differences between groups. Propensity-score matching, IPTW, or stratification by key covariates should be applied before plotting the comparison curves so that the visual comparison is not confounded by selection bias.

My KM curves cross — what should I do?

Crossing curves violate the proportional-hazards assumption and make the log-rank test misleading as a summary statistic. Report restricted mean survival time (RMST) up to a clinically meaningful time horizon instead, as RMST remains interpretable and valid when curves cross. Also examine whether a competing-risks framework is more appropriate.

How is this different from a Cox model in a pragmatic study?

Kaplan-Meier is non-parametric and produces a visual survival curve without modeling covariates. Cox proportional hazards regression estimates hazard ratios while adjusting for multiple covariates simultaneously. In a pragmatic analysis the two are complementary: KM curves provide the unadjusted (or post-weighting) visual summary; Cox regression provides confounder-adjusted hazard ratio estimates. Use both when reporting.

Can Kaplan-Meier be used with electronic health record data?

Yes, and this is one of the most common pragmatic applications. EHR-linked data provide large samples and long follow-up. Key requirements are reliable event capture (ICD codes, mortality linkage), a clear index date, and careful handling of informative censoring — patients who switch provider or disenroll may not be missing at random, which can bias the survival estimate.

Sources

  1. Kaplan, E. L., & Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53(282), 457–481. DOI: 10.1080/01621459.1958.10501452 ↗
  2. Schwartz, D., & Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases, 20(8), 637–648. DOI: 10.1016/0021-9681(67)90041-0 ↗

How to cite this page

ScholarGate. (2026, June 3). Pragmatic Kaplan-Meier Survival Analysis. ScholarGate. https://scholargate.app/en/epidemiology/pragmatic-kaplan-meier-analysis

Related methods

Cox proportional hazardsKaplan-Meier AnalysisLog-Rank TestPragmatic randomized clinical trialSurvival Analysis

Which method?

Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.

  • Cox proportional hazardsEpidemiology↔ compare
  • Kaplan-Meier AnalysisEpidemiology↔ compare
  • Log-Rank TestSurvival↔ compare
  • Pragmatic randomized clinical trialEpidemiology↔ compare
  • Survival AnalysisResearch Statistics↔ compare
Compare side by side →

Similar methods

Pragmatic survival analysisKaplan-Meier AnalysisKaplan-Meier EstimatorRetrospective Kaplan-Meier AnalysisKaplan-MeierMulticenter Kaplan-Meier analysisMatched Kaplan-Meier AnalysisSurvival Analysis

Related reference concepts

Kaplan-Meier Survival CurvesSurvival Analysis and Time-to-Event MethodsCensoring and Follow-Up DataCox Regression ModelsCompeting RisksProportional Hazards Assumption

Spotted an issue on this page? Report or suggest a fix →

ScholarGate — Pragmatic Kaplan-Meier analysis (Pragmatic Kaplan-Meier Survival Analysis). Retrieved 2026-07-21 from https://scholargate.app/en/epidemiology/pragmatic-kaplan-meier-analysis · Dataset: https://doi.org/10.5281/zenodo.20539026
Quick facts
Originator
Kaplan & Meier (estimator, 1958); Schwartz & Lellouch (pragmatic trial framework, 1967)
Year
1958 (estimator); pragmatic application formalized 1967 onward
Type
Non-parametric survival estimator within pragmatic study design
DataType
Time-to-event data with censoring from real-world or pragmatic clinical settings
Subfamily
Clinical / epidemiology
Related methods
Cox proportional hazardsKaplan-Meier AnalysisLog-Rank TestPragmatic randomized clinical trialSurvival Analysis
ScholarGate

A content-first reference library for research methods — what each one is, how it works, and where it comes from.

Open data (CC-BY)

Explore

  • Library
  • Search the library…
  • Browse by field
  • Fields
  • Journey
  • Compare
  • Which method?

Reference

  • Subjects
  • Atlas
  • Glossary
  • Methodology
  • Philosophy

Your tools

  • Bookshelf
  • Desk
  • Chat

Company

  • About
  • Pricing
  • Contact
  • Suggest a method

Entries are compiled from published sources for reference. Verifying the accuracy and suitability of any information for your own use remains your responsibility.

© 2026 ScholarGate · A research-method reference library
  • Privacy
  • Cookies
  • Terms
  • Delete account